{"id":"NCT01194570","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis","officialTitle":"A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-02","primaryCompletion":"2015-07-23","completion":"2022-12-31","firstPosted":"2010-09-03","resultsPosted":"2017-12-26","lastUpdate":"2024-01-10"},"enrollment":735,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Primary Progressive"],"interventions":[{"type":"DRUG","name":"Ocrelizumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"EXPERIMENTAL"},{"label":"Ocrelizumab 600 mg","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.","primaryOutcome":{"measure":"Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period","timeFrame":"Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm","effectByArm":[{"arm":"Placebo","deltaMin":null,"sd":null},{"arm":"Ocrelizumab 600 mg","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":184,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Finland","France","Germany","Greece","Hungary","Israel","Italy","Lithuania","Mexico","Netherlands","New Zealand","Norway","Peru","Poland","Portugal","Romania","Russia","Spain","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["40258203","38071574","37652990","36792367","36163349","35672926","33724638","33129442","30415593","30155979","28002688"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":239},"commonTop":["INFUSION RELATED REACTION","URINARY TRACT INFECTION","NASOPHARYNGITIS","BACK PAIN","ARTHRALGIA"]}}